Abbott Laboratories (ABT) Gets a Buy from RBC Capital
In a report released on January 17, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Abbott Laboratories (ABT – Research ...
UBS initiates Penumbra shares with Buy rating, projects 14% revenue CAGR through 2029
UBS initiated coverage on Penumbra (NYSE:PEN), a medical technology company, with a Buy rating and a price target of $305.00. Trading at $263.69 and with a market capitalization of $10.12 billion, the ...
Early-stage biotechs may soon get their swagger back, say industry leaders
In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, ...